Bayer Acquires Perfuse for $2.45B
May 6, 2026
Bayer to buy Perfuse Therapeutics for $300M upfront + $2.15B milestones for Phase 2 PER-001 in glaucoma and diabetic retinopathy.
Bayer Preps Kerendia CKD Label Expansion
March 16, 2026
Bayer's Phase III FIND-CKD trial met its endpoint in non-diabetic CKD, teeing up a major label expansion for finerenone (Kerendia) beyond diabetes-associated cases.
Eylea Biosimilar Gains UK/EEA Launch Dates
January 30, 2026
ADVANZ and Alvotech settle Eylea patents with Bayer/Regeneron, enabling UK launch Jan 1 2026 and EEA/Switzerland May 1 2026.